戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ing sign during the follow-up of extrafacial lentigo.
2 ndents had at >=1 pigmentary disorder: solar lentigo (13,192 [27.5%]), axillary hyperpigmentation (82
3  Histological melanocytic changes resembling lentigo and lentigo maligna were seen in several skin gr
4 c nevi, angiokeratoma, dermatofibroma, solar lentigo, and seborrheic keratosis were measured.
5                            The management of lentigo maligna (LM) and LM melanoma (LMM) is challengin
6                           SEER data revealed lentigo maligna (LM) as the most prevalent in situ subty
7 systematically evaluated for the presence of lentigo maligna (LM) criteria.
8                                              Lentigo maligna (LM) is a clinical, pathologic, and ther
9 e on the rate of local recurrence of the non-lentigo maligna (non-LM)/non-acral lentiginous melanoma
10 btypes include superficial spreading (~70%), lentigo maligna (~15%), nodular (~5%), desmoplastic (~4%
11                 The diagnosis of extrafacial lentigo maligna can be a challenge because the dermoscop
12 n facial lesions and was associated with the lentigo maligna histologic subtype.
13 n AM (44.4%) and occasional amplification in lentigo maligna melanoma (10.5%) and superficial spreadi
14                                   Worldwide, lentigo maligna melanoma (LMM) comprises 4%-15% of cutan
15 ing basal cell cancer, squamous cell cancer, lentigo maligna melanoma and cutaneous T-cell lymphoma.
16 e associated with age at diagnosis 65 years, lentigo maligna melanoma histologic subtype, presence of
17 associated with age at diagnosis >=65 years, lentigo maligna melanoma histologic subtype, presence of
18 an 1/mm2, and acral lentiginous melanoma and lentigo maligna melanoma subtypes were associated with a
19  an axial site, and superficial spreading or lentigo maligna melanoma types (P = .02, P < .001, and P
20 ysis showed that acral lentiginous melanoma, lentigo maligna melanoma, and increasing Breslow thickne
21 cardia and Meniere's disease, bimatoprost to lentigo maligna melanoma, and tafluprost to labyrinthiti
22 rs, as well as cutaneous T-cell lymphoma and lentigo maligna melanoma.
23 001) and nonnodular subtype (lentigo maligna/lentigo maligna melanoma: HR, 0.743; 95% CI, 0.686-0.805
24                      Melanomas classified as lentigo maligna melanomas or as occurring on severely su
25 preading melanomas, 17 nodular melanomas, 19 lentigo maligna melanomas, 18 AMs, and 12 unclassifiable
26  (100%) mucosal melanoma and two of 10 (20%) lentigo maligna melanomas.
27                  The pathologic diagnosis of lentigo maligna was established in each case.
28                                              Lentigo maligna was the most frequent subtype of melanom
29 l melanocytic changes resembling lentigo and lentigo maligna were seen in several skin grafts treated
30 l spreading subtype (nodular, 0.5 [0.2-1.0]; lentigo maligna, 0.4 [0.2-0.7]; and unclassified/other,
31 n into four subtypes: superficial spreading, lentigo maligna, nodular, and acral lentiginous.
32 29.4% vs 8.7%; P < .001) and of the nodular, lentigo maligna, or acral lentiginous histologic subtype
33 680-0.716; P < .001) and nonnodular subtype (lentigo maligna/lentigo maligna melanoma: HR, 0.743; 95%
34   Imiquimod leads to an 80-100% cure rate of lentigo maligna; however, studies of invasive melanoma a
35 ficial spreading melanoma and some of facial lentigo maligna; however, these features are often absen
36  which was excised and showed nevus or solar lentigo on histopathology.
37 benign keratinocytic lesions including solar lentigo, seborrheic keratosis and lichen planus-like ker